Abstract:Jun Shao, &ast Yunru Gu, &ast Renhua Guo, Jiali Xu Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Renhua Guo; Jiali Xu, Email ; Purpose: Activating mutations in epidermal growth factor receptor (EGFR) have been identified as key predictive biomarkers for the customized treatment with EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC), aiding in improving patient response rates and survival. However, resistance challenges the efficacy of these treatments, with limited understanding of post-resistance therapeutic strategies. A deep understanding of the biology and resistance mechanisms of EGFR-mutant NSCLC is crucial for developing new treatment approaches. This study, through bibliometric analysis, summarizes the trends in research on resistance to EGFR-TKIs. Methods: Research papers on NSCLC with EGFR inhibitor resistance were collected from the Web of Science Core Collection (WoSCC). The analysis utilized bibliometric tools like CiteSpace, VOSviewer, and other platforms for comprehensive analysis and visualization of the outcomes. Results: The WoSCC database contains a total of 5866 documents on resistance to EGFR-TKIs treatment, including 4727 articles (93.48%) and 1139 reviews (6.52%), spanning 81 countries and regions, 4792 institutions, with the involvement of 23,594 authors. Since 2016, there has been a significant increase in publications in this field. China has the highest publication output, while the United States has the highest citation count for papers. Harvard University leads in terms of the number of publications. Among the top ten journals with the highest output, Clinical Cancer Research has the highest impact factor at 11.5, with 90% of the journals classified in Q1 or Q2. Rafael Rosell is one of the most influential authors in this field, ranking second in publication volume and fourth in citation count. Research on EGFR-TKIs resistance mainly focuses on genetic testing, resistance mechanisms, and post-resistance treatment strategies. Conclusion: This study provides researchers with a reliable basis and guidance for finding authoritative references, understanding research trends, and exploring potential directions. Keywords: NSCLC, EGFR mutation, EGFR-TKIs, bibliometric analysis, hot SPOTS Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, accounting for about 85% of cases. It primarily includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. 1 The EGFR is a transmembrane glycoprotein with tyrosine kinase activity that plays a crucial role in physiological processes such as cell growth, proliferation, and differentiation through its phosphorylation. EGFR gene mutations are the most common driver gene mutations in NSCLC. Their primary mechanism of action is to regulate tumor cell proliferation, angiogenesis, and tumor cell invasion and metastasis by binding to extracellular ligands and undergoing homologous or heterologous dimerization. 2,3 Especially in the Chinese NSCLC population, the proportion of EGFR mutations is 28.2%, and in lung adenocarcinoma, this proportion rises to 50.2%. 4 The emergence of EGFR tyrosine kinase inhibitors (TKIs) has changed the standard treatment paradigm for patients with advanced EGFR mutation-positive NSCLC. TKIs have been evaluated and recommended as a first-line treatment option for patients with EGFR mutation-positive NSCLC by current treatment guidelines, including the National Comprehensive Cancer Network (NCCN). 5 Compared to traditional platinum-based chemotherapy, first- and second-generation EGFR-TKIs as first-line treatment for advanced NSCLC with classic EGFR mutations (deletions in EGFR exon 19 or L858R point mutations in exon 21) significantly improve median progression-free survival (mPFS) but not overall survival (OS). 6–8 Approximately 50%-60% of patients treated with first- or second-generation EGFR-TKIs as first-line therapy will develop secondary T790M resistance mutations. 9 Third-generation EGFR-TKIs can inhibit both EGFR-sensitive mutations and T790M resistance mutations, significantly increasing mPFS by about 10 months compared to first/second-generation EGFR-TKIs in patients with EGFR-sensitive mutations. 10–12 In the FLAURA study, Osimertinib achieved a statistically and clinically significant improvement in OS, extending it to 38.6 months (compared to 31.8 months in the control group, p=0.046). The results of the FLAURA2 study (comparing the efficacy and safety of Osimertinib in combination with chemotherapy versus -Abstract Truncated-

Lung Adenocarcinoma Resistance to Therapy with EGFR‑tyrosine Kinase Inhibitors is Related to Increased Expression of Cancer Stem Cell Markers SOX2, OCT4 and NANOG.

TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer

Factors That Predict Progression-Free Survival in Chinese Lung Adenocarcinoma Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Efficacy and Predictors of Egfr Tyrosine Kinase Inhibitors in Chinese Advanced Lung Adenocarcinoma: Analyses of 253 Cases from A Single Institute

[Correlation Between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].

Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.

High Expression of Octamer-Binding Transcription Factor 4a, Prominin-1 and Aldehyde Dehydrogenase Strongly Indicates Involvement in the Initiation of Lung Adenocarcinoma Resulting in Shorter Disease-Free Intervals

Low infiltration of CD8+ FOXP3+ T cells associated with favorable clinical outcomes after first-line targeted therapy in EGFR exon 21 mutated lung adenocarcinoma patients.

EGFR-Mutated Squamous Cell Lung Cancer and Its Association with Outcomes.

Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas

Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs]

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Different First Line EGFR-TKI Regimen and the Clearance of EGFR Sensitive Mutation in Acquired EGFR-TKI Resistant Lung Adenocarcinoma Patients

EGFR with TKI-sensitive Mutations in Exon 19 is Highly Expressed and Frequently Detected in Chinese Patients with Lung Squamous Carcinoma.

Effect of Strong Programmed Cell Death Ligand-1 (PD-L1) Expressions on Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.

Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC

Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness